Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1440.898
- +2.789+0.19%
Beam Therapeutics Gets Trial Authorization for Its Genetic Disorder Treatment in U.S.
Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For Treatment Of Alpha-1 Antitrypsin Deficiency By The U.S. FDA
Merck Inks a Licensing Deal Worth Nearly $2B With China's Jiangsu Hengrui
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Top 10 S&P 500 Performers of 2025 All Returned Over 20% as the Broader Index Struggles
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Express News | FOMC Projects Lower GDP and Uncertainty, No Rate Change
Fed Dot Plot in Full View as Market Holds on a Higher Note: Live Stock News
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Caribou Biosciences Analyst Ratings
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
Sangamo Therapeutics Analyst Ratings
Green Gives Way to Red on Gossamer Macro Expectations: Live Stock News
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday
Earnings Call Summary | Sangamo Therapeutics(SGMO.US) Q4 2024 Earnings Conference
Sangamo Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 Financial Results.
Sangamo Therapeutics Expects FY25 Operating Expenses On A Non-GAAP Basis Are To Be Roughly In Line With 2024
Monday Market Green Like the Irish, But for How Long: Live Stock News
Here Are the Major Earnings After the Close Today